曲妥珠单抗治疗HER2+乳腺癌的临床进展探析

Analysis of clinical progress of trudezumab in the treatment of HER2+breast cancer

乳腺癌是危害女性健康的恶性肿瘤疾病,发病率呈逐年上升趋势。HER2+乳腺癌由于侵袭性高,且预后质量差,一直是临床研究的重点。曲妥珠单抗的临床应用,很大程度地改善了HER2+乳腺癌患者的预后质量,但在治疗后会出现耐药性和不良反应,对曲妥珠单抗大面积推广产生了影响。因此,在当前标准治疗中加入新的抗HER2药物,成为现阶段临床研究热点。文章从联合化疗、联合内分泌治疗、联合其他靶向药物治疗HER2+早期乳腺癌的临床进展进行综述。

Breast cancer is a malignant tumor disease that endangers women's health,the morbidity is increasing year by year.HER2+breast cancer has been the focus of clinical research because of its high invasiveness and poor prognosis.Trastuzumab in clinical application of HER2+mammary cancer has greatly improved the prognosis.However,drug resistance and adverse reactions after treatment have effects on the large area promotion of trastuzumab,therefore,the addition of new anti-HER2 drugs to the existing standard therapy has become a hot topic in clinical research at the present stage.This article reviews the clinical progress of the trastuzumab therapy on HER2+breast cancer from the aspects of combined chemotherapy,combined endocrine therapy and combined with other targeted therapy drugs.